Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines

被引：5

作者：

Italiano, A. ^{[1
]}

Toulmonde, M. ^{[1
]}

Bui-Nguyen, B. ^{[1
]}

机构：

[1] Inst Bergonie, Dept Med Oncol, F-33076 Bordeaux, France

来源：

BULLETIN DU CANCER | 2010年 / 97卷 / 06期

关键词：

sarcoma; chemotherapy; anthracyclines; ifosfamide; trabectedin; gemcitabine; HIGH-DOSE IFOSFAMIDE; PHASE-II TRIAL; EUROPEAN-ORGANIZATION; BONE; ECTEINASCIDIN-743; GEMCITABINE; DOCETAXEL; AGENT; MESNA; ANGIOSARCOMA;

D O I：

10.1684/bdc.2010.1119

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Doxorubicin monotherapy is the standard first-line treatment in patients with advanced soft-tissue sarcomas. Ifosfamide still remains the standard 2nd line treatment after doxorubicin-failure. However, recent data have demonstrated that histological subtypes differ in their sensitivity to cytotoxic drugs. Therefore, gemcitabine should be considered as the best option after doxorubicin failure in leiomyosarcoma patients. Trabectedine should be used preferentially in myxoid liposarcomas and leiomyosarcomas patients whereas paclitaxel should be considered as a first or second-line treatment of choice in angiosarcoma patients. Further studies are needed in order to identify predictive factors of clinical benefit in advanced soft-tissue sarcoma patients treated with cytotoxic agents in combination or not with targeted therapies.

引用

页码：679 / 686

页数：8

共 50 条

[1] RESPONSE TO IFOSFAMIDE AND MESNA - 124 PREVIOUSLY TREATED PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA [J].

ANTMAN, KH ;

RYAN, L ;

ELIAS, A ;

SHERMAN, D ;

GRIER, HE .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :126-131

[2]

BENJAMIN RS, 1993, CANCER CHEMOTH PHARM, V31, pS174

[3]

BLAY J, 2009, J CLIN ONCOL S, V27, pS15

[4] Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study [J].

Brain, E. G. C. ;

Rezai, K. ;

Weill, S. ;

Gauzan, M. F. ;

Santoni, J. ;

Besse, B. ;

Goupil, A. ;

Turpin, F. ;

Urien, S. ;

Lokiec, F. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (03) :375-381

[5]

Bramwell VH., 2003, COCHRANE DB SYST REV, V3, pCD003293, DOI DOI 10.1002/14651858.CD003293

[6] HIGH-DOSE DTIC IN ADVANCED SOFT-TISSUE SARCOMAS IN THE ADULT - A PHASE II STUDY OF THE EORTC SOFT-TISSUE AND BONE-SARCOMA-GROUP [J].

BUESA, JM ;

MOURIDSEN, HT ;

VANOOSTEROM, AT ;

VERWEIJ, J ;

WAGENER, T ;

STEWARD, W ;

POVEDA, A ;

VESTLEV, PM ;

THOMAS, D ;

SYLVESTER, R .

ANNALS OF ONCOLOGY, 1991, 2 (04) :307-309

[7] Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF:: A pharmacokinetic study in advanced sarcoma patients [J].

Cerny, T ;

Leyvraz, S ;

von Briel, T ;

Küpfer, A ;

Schaad, R ;

Schmitz, SFH ;

Honegger, P ;

Sessa, C ;

Brunner, J ;

Boddy, AV .

ANNALS OF ONCOLOGY, 1999, 10 (09) :1087-1094

[8] Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients - Preliminary evidence of activity [J].

Delaloge, S ;

Yovine, A ;

Taamma, A ;

Riofrio, M ;

Brain, E ;

Raymond, E ;

Cottu, P ;

Goldwasser, F ;

Jimeno, J ;

Misset, JL ;

Marty, M ;

Cvitkovic, E .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1248-1255

[9]

DEMETRI G, 2009, J CLIN ONCOL S, V27, pS15

[10] HIGH-DOSE IFOSFAMIDE WITH MESNA UROPROTECTION - A PHASE-I STUDY [J].

ELIAS, AD ;

EDER, JP ;

SHEA, T ;

BEGG, CB ;

FREI, E ;

ANTMAN, KH .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) :170-178

← 1 2 3 4 5 →